Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757842 | 0.85 | MMP3 (0.46) | CA12CA9CA2CA3CA6 | |
| SCHEMBL27577154 | 0.85 | TTR (0.39) | TTRALBCA12CA9CA2 | |
| SCHEMBL30529523 | 0.84 | TTR (0.38) | TTRALBCA12CA9CA2 | |
| SCHEMBL21383715 | 0.84 | TTR (0.38) | TTRALBCA12CA9CA2 | |
| SCHEMBL3872780 | 0.81 | GSK3B (0.39) | CA12CA9CA2CA3CA6 | |
| SCHEMBL6483113 | 0.80 | LOXL2 (0.47) | TTRALBCA12CA9CA2 | |
| SCHEMBL27176926 | 0.80 | TTR (0.47) | TTRALBCA12CA9CA2 | |
| Hydrochloric Acid SCHEMBL6475550 | 0.78 | LOXL2 (0.45) | TTRALBCA12CA9CA2 | |
| SCHEMBL29529580 | 0.78 | MEN1 (0.43) | TTRALBCA12CA9CA2 | |
| SCHEMBL409734 | 0.78 | MEN1 (0.43) | TTRALBCA12CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615573-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| WO-2024102625-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4341255-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230234973-A1 | INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG | HERON NEUTRON MEDICAL CORP. (TW) | 2023-07-27 | — | — | US | disclosed |
| WO-2022246019-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-11-24 | — | — | WO | disclosed |
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | TTR 1644/4885ALB 778/4885CA12 1486/4885 |
| US-20230234973-A1 | INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG | CYP2F1, SULT1A1, CYP4F3 | TTR 2481/4885ALB 2053/4885CA12 2868/4885 |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | TTR 1475/4885ALB 3536/4885CA12 4558/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | TTR 764/4885ALB 3091/4885CA12 4064/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | TTR 988/4885ALB 3659/4885CA12 4050/4885 |
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | TTR 1082/4885ALB 3605/4885CA12 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.